These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16050270)

  • 1. Cellular mechanisms of Torsade de Pointes.
    Poelzing S; Rosenbaum DS
    Novartis Found Symp; 2005; 266():204-17; discussion 217-24. PubMed ID: 16050270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular biology and cellular mechanisms of Brugada and long QT syndromes in infants and young children.
    Antzelevitch C
    J Electrocardiol; 2001; 34 Suppl():177-81. PubMed ID: 11781953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular predictors of drug-induced prolongation of the QT interval.
    Dilaveris PE
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetics of acquired long QT syndrome.
    Roden DM; Viswanathan PC
    J Clin Invest; 2005 Aug; 115(8):2025-32. PubMed ID: 16075043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inherited long QT syndrome: from ion channel to bedside.
    Vincent GM; Timothy K; Fox J; Zhang L
    Cardiol Rev; 1999; 7(1):44-55. PubMed ID: 10348966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death.
    Vincent GM
    Annu Rev Med; 1998; 49():263-74. PubMed ID: 9509262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability).
    Hondeghem LM
    Novartis Found Symp; 2005; 266():235-44; discussion 244-50. PubMed ID: 16050272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome.
    Akar FG; Yan GX; Antzelevitch C; Rosenbaum DS
    Circulation; 2002 Mar; 105(10):1247-53. PubMed ID: 11889021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.
    Zünkler BJ
    Pharmacol Ther; 2006 Oct; 112(1):12-37. PubMed ID: 16647758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes.
    Antzelevitch C
    Europace; 2007 Sep; 9 Suppl 4(Suppl 4):iv4-15. PubMed ID: 17766323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of models for predicting Torsade de Pointes cardiac arrhythmias using perceptron neural networks.
    Sharifi M; Buzatu D; Harris S; Wilkes J
    BMC Bioinformatics; 2017 Dec; 18(Suppl 14):497. PubMed ID: 29297274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes.
    Sun Z; Milos PM; Thompson JF; Lloyd DB; Mank-Seymour A; Richmond J; Cordes JS; Zhou J
    J Mol Cell Cardiol; 2004 Nov; 37(5):1031-9. PubMed ID: 15522280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
    Hayashi K; Shimizu M; Ino H; Yamaguchi M; Terai H; Hoshi N; Higashida H; Terashima N; Uno Y; Kanaya H; Mabuchi H
    Clin Sci (Lond); 2004 Aug; 107(2):175-82. PubMed ID: 15043509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
    Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
    Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arrhythmogenicity of Anti-Ro/SSA Antibodies in Patients With Torsades de Pointes.
    Lazzerini PE; Yue Y; Srivastava U; Fabris F; Capecchi PL; Bertolozzi I; Bacarelli MR; Morozzi G; Acampa M; Natale M; El-Sherif N; Galeazzi M; Laghi-Pasini F; Boutjdir M
    Circ Arrhythm Electrophysiol; 2016 Apr; 9(4):e003419. PubMed ID: 27030700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology.
    Priori SG; Cantù F; Schwartz PJ
    Schweiz Med Wochenschr; 1996 Oct; 126(41):1727-31. PubMed ID: 8893413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
    Finlayson K; Witchel HJ; McCulloch J; Sharkey J
    Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.
    Sala M; Coppa F; Cappucciati C; Brambilla P; d'Allio G; Caverzasi E; Barale F; De Ferrari GM
    Curr Opin Investig Drugs; 2006 Mar; 7(3):256-63. PubMed ID: 16555686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Torsades de pointes during complete atrioventricular block: Genetic factors and electrocardiogram correlates.
    Subbiah RN; Gollob MH; Gula LJ; Davies RW; Leong-Sit P; Skanes AC; Yee R; Klein GJ; Krahn AD
    Can J Cardiol; 2010 Apr; 26(4):208-12. PubMed ID: 20386770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
    Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
    Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.